common.study.topics.clinical

Lorlatinib Renal Impairment Study

common.study.values.description

“Lorlatinib Renal Impairment Study”

This is a Phase 1, open-label, multi-center, single treatment study in subjects with normal renal function and varying degrees of renal impairment.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Lorlatinib

Lorlatinib single oral dose

participant.views.study.view.additional

participant.views.study.view.scientific-title

A PHASE 1, SINGLE DOSE OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF LORLATINIB IN SUBJECTS WITH IMPAIRED RENAL FUNCTION

common.study.values.clinical-trial-id

NCT03542305

participant.views.study.view.id

QeZlQb